Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer Terms Canadian News Report Questioning Celebrex Safety

By Pharmaceutical Processing | November 8, 2004

NEW YORK, NY (November 8, 2004) – Pfizer Inc. last week labeled “misleading” a report in Canada’s National Post newspaper concerning the cardiovascular safety of Celebrex.

Pfizer said the news report was based on voluntary spontaneous event reporting to Canadian Health authorities and was “not supported by any clinical or epidemiological studies.” The company said the report “has the potential to cause undue confusion among patients and physicians.”

“The safety profile for Celebrex is well-established and is supported by extensive clinical studies in Canada and around the world,” Pfizer said in a statement issued Thursday.

Voluntary spontaneous event reporting to health authorities is not designed and cannot be used to determine cause and effect, the company said. “It is essential to remember that the information provided is uncontrolled and may be second-hand or incomplete,” the Pfizer statement continued.

According to Pfizer, Health Canada has acknowledged these limitations, noting “there hasn’t been a causal link established,” and that “these datacontain no information about patients’ underlying medical conditions.”

Pfizer said that millions of patients have been prescribed Celebrex since its first approval in 1998 and large-scale clinical studies of up to four years showed no increased cardiovascular safety risk.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards